Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|November 15, 2024
Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USAXiaomo Xiong, Jeff Jianfei Guo
Therapeutic Advances in Drug Safety|January 5, 2026
Medication errors and associated serious outcomes in COVID-19 antivirals: a real-world study based on FDA Adverse Event Reporting System databaseXiaomo Xiong, Zhanghe Chen, Bingfang Yan
Frontiers in Medicine|July 5, 2021
Effect of Cost-Related Medication Non-adherence Among Older Adults With Medication Therapy ManagementWeiwei Zhang, Gang Lv, Xiaomo Xiong, et al.
Frontiers in Medicine|May 31, 2021
Mortality Rate and Characteristics of Deaths Following COVID-19 VaccinationGang Lv, Jing Yuan, Xiaomo Xiong, et al.
BMJ Global Health|September 14, 2021
Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in ChinaJing Yuan, Z Kevin Lu, Xiaomo Xiong, et al.
Frontiers in Pharmacology|September 13, 2021
Gender Disparities in Anti-dementia Medication Use among Older Adults: Health Equity Considerations and Management of Alzheimer's Disease and Related DementiasZ Kevin Lu, Xiaomo Xiong, Xinyuan Wang, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 8, 2018
The quality of life in Chinese population with chronic non-communicable diseases according to EQ-5D-3L: a systematic reviewTing Zhou, Haijing Guan, Jiaqi Yao, et al.
BMJ Open|May 4, 2022
Impact of financial barriers on health status, healthcare utilisation and economic burden among individuals with cognitive impairment: a national cross-sectional surveyKevin Lu, Xiaomo Xiong, Ashley Horras, et al.
Frontiers in Medicine|August 5, 2021
Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk ManagementXiaomo Xiong, Jing Yuan, Minghui Li, et al.
Journal of Alzheimer'S Disease : JAD|March 16, 2026
Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic reviewXiangxiang Jiang, Gang Lv, Xiaomo Xiong, et al.
Pageof 3